Refine
Has Fulltext
- yes (17)
Is part of the Bibliography
- no (17)
Keywords
- autophagy (2)
- 3Cs technology (1)
- ATG3 (1)
- Angiogenesis (1)
- Animal models (1)
- Apoptosis (1)
- CRISPR/Cas (1)
- Cardiology (1)
- Cell division (1)
- Checkpoints (1)
- Crispr/Cas (1)
- DUBs (1)
- Doxorubicin (1)
- Genome editing (1)
- HIPPO signalling (1)
- LAMTOR1 (1)
- Long non-coding RNAs (1)
- Metabolism (1)
- RNAi and CRISPR screens (1)
- Rab7 (1)
- Ragulator complex (1)
- TOR signalling (1)
- Tools and ressources (1)
- USP32 (1)
- acute myeloid leukemia (1)
- autophagy inhibition (1)
- cancer and drug vulnerabilities (1)
- cell biology (1)
- chemotherapy resistance (1)
- deubiquitinase (DUB) (1)
- functional genomics (1)
- gRNA library (1)
- genetics and genomics (1)
- genome-wide (1)
- human (1)
- mTORC1 (1)
- metabolic rewiring (1)
- ubiquitin (1)
- v-ATPase (1)
Institute
- Medizin (16)
- Biochemie und Chemie (3)
- Biowissenschaften (3)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (2)
- Exzellenzcluster Makromolekulare Komplexe (2)
- Georg-Speyer-Haus (2)
- Biodiversität und Klima Forschungszentrum (BiK-F) (1)
- Senckenbergische Naturforschende Gesellschaft (1)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (1)
Drug resistance is a commonly unavoidable consequence of cancer treatment that results in therapy failure and disease relapse. Intrinsic (pre-existing) or acquired resistance mechanisms can be drug-specific or be applicable to multiple drugs, resulting in multidrug resistance. The presence of drug resistance is, however, tightly coupled to changes in cellular homeostasis, which can lead to resistance-coupled vulnerabilities. Unbiased gene perturbations through RNAi and CRISPR technologies are invaluable tools to establish genotype-to-phenotype relationships at the genome scale. Moreover, their application to cancer cell lines can uncover new vulnerabilities that are associated with resistance mechanisms. Here, we discuss targeted and unbiased RNAi and CRISPR efforts in the discovery of drug resistance mechanisms by focusing on first-in-line chemotherapy and their enforced vulnerabilities, and we present a view forward on which measures should be taken to accelerate their clinical translation.